CD18HYP and CD18KO LAD-I mice given vector-transduced murine Lin- cells: engraftment and enhanced neutrophil extravasation to inflamed sites
“Successful engraftment of the Chim-CD18-WPRE LV transduced Lin- cells was demonstrated in recipient CD18HYP or CD18KO mice with enhanced neutrophil extravasation to tissue-specific sites of inflammation.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Why that model
Insufficient LAD-I patient CD34+ cells available, so surrogate murine HSPCs and healthy-donor CD34+ cells were used
“The final clinical product and source material was not used in the nonclinical studies summarized in this memo due to feasibility issues obtaining sufficient CD34+ HSCs from LAD-I patients.”
✓ VerifiedFDA pharmacology/toxicology review, p. 8Source ↗
Reviewer's view of the efficacy data
FDA: no nonclinical deficiencies and no further testing requested; data support approval
“There are no nonclinical deficiencies in the pharmacology/toxicology studies. There are no requests for further nonclinical testing of KRESLADITM.”
✓ VerifiedFDA pharmacology/toxicology review, p. 4Source ↗
WAS-deficient mice transplanted with WAS LVV-transduced murine Lin- BM cells: increased B cells, platelets, granulocytes; improved T, B and DC function